A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Debio 1347 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors Debiopharm Group
- 01 Apr 2019 According to Debiopharm media release, data from this trial were presented at the 2019 Annual AACR meeting in Atlanta, Georgia.
- 27 Mar 2019 Planned number of patients changed from 112 to 118.
- 27 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History